Fostamatinib and the risk of acute aortic dissection in immune thrombocytopenia Article Swipe
Paul Dalmas
,
Alexis Théron
,
Rita Badaoui
,
Stéphane Zaffran
,
Rayid Mchinda
,
Joëlle Micallef
,
N. Schleinitz
,
Mikaël Ebbo
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1002/bcp.70289
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1002/bcp.70289
Immune thrombocytopenia (ITP) is a rare autoimmune disorder characterized by platelet destruction. While most patients respond to first‐ or second‐line therapies, a small subset is multirefractory. Fostamatinib , an oral spleen tyrosine kinase ( SYK ) inhibitor, is a therapeutic option in these cases. We report a case of an acute aortic dissection (AAD) occurring in a patient without traditional cardiovascular risk factors, 3 months after fostamatinib initiation. A 70‐year‐old woman with a 30‐year history of ITP, unresponsive to multiple therapies, was treated with fostamatinib and achieved a complete haematologic response. She presented with sudden chest pain and was diagnosed with Stanford A (DeBakey type 1) AAD requiring emergency surgery. Histological analysis of her aortic tissue showed a 25% reduction in phosphorylated SYK expression compared to a control sample, without alteration in smooth muscle cell markers. The absence of predisposing conditions (hypertension, smoking, genetic disorders) led us to explore a potential link between fostamatinib and AAD. Experimental data suggest that SYK inhibition exacerbates aortic wall vulnerability, and off‐target effects of fostamatinib on VEGF receptors may further weaken vascular integrity. This case highlights a possible association between fostamatinib and AAD, potentially mediated by SYK and VEGFR inhibition. While causality cannot be definitively established, clinicians should be vigilant when prescribing fostamatinib, even in patients without known risk factors for AAD. Further studies are needed to clarify the vascular safety profile of fostamatinib in ITP and other settings.
Related Topics
Concepts
No concepts available.
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1002/bcp.70289
- https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bcp.70289
- OA Status
- hybrid
- References
- 17
- OpenAlex ID
- https://openalex.org/W4414308957
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4414308957Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1002/bcp.70289Digital Object Identifier
- Title
-
Fostamatinib and the risk of acute aortic dissection in immune thrombocytopeniaWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-09-17Full publication date if available
- Authors
-
Paul Dalmas, Alexis Théron, Rita Badaoui, Stéphane Zaffran, Rayid Mchinda, Joëlle Micallef, N. Schleinitz, Mikaël EbboList of authors in order
- Landing page
-
https://doi.org/10.1002/bcp.70289Publisher landing page
- PDF URL
-
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bcp.70289Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
hybridOpen access status per OpenAlex
- OA URL
-
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bcp.70289Direct OA link when available
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
17Number of works referenced by this work
Full payload
| id | https://openalex.org/W4414308957 |
|---|---|
| doi | https://doi.org/10.1002/bcp.70289 |
| ids.doi | https://doi.org/10.1002/bcp.70289 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/40962713 |
| ids.openalex | https://openalex.org/W4414308957 |
| fwci | 0.0 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | |
| mesh[1].descriptor_ui | D005260 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | |
| mesh[1].descriptor_name | Female |
| mesh[2].qualifier_ui | |
| mesh[2].descriptor_ui | D000368 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | |
| mesh[2].descriptor_name | Aged |
| mesh[3].qualifier_ui | Q000139 |
| mesh[3].descriptor_ui | D000784 |
| mesh[3].is_major_topic | True |
| mesh[3].qualifier_name | chemically induced |
| mesh[3].descriptor_name | Aortic Dissection |
| mesh[4].qualifier_ui | Q000175 |
| mesh[4].descriptor_ui | D000784 |
| mesh[4].is_major_topic | True |
| mesh[4].qualifier_name | diagnosis |
| mesh[4].descriptor_name | Aortic Dissection |
| mesh[5].qualifier_ui | Q000037 |
| mesh[5].descriptor_ui | D000072377 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | antagonists & inhibitors |
| mesh[5].descriptor_name | Syk Kinase |
| mesh[6].qualifier_ui | Q000009 |
| mesh[6].descriptor_ui | D010078 |
| mesh[6].is_major_topic | True |
| mesh[6].qualifier_name | adverse effects |
| mesh[6].descriptor_name | Oxazines |
| mesh[7].qualifier_ui | Q000627 |
| mesh[7].descriptor_ui | D010078 |
| mesh[7].is_major_topic | True |
| mesh[7].qualifier_name | therapeutic use |
| mesh[7].descriptor_name | Oxazines |
| mesh[8].qualifier_ui | Q000188 |
| mesh[8].descriptor_ui | D016553 |
| mesh[8].is_major_topic | True |
| mesh[8].qualifier_name | drug therapy |
| mesh[8].descriptor_name | Purpura, Thrombocytopenic, Idiopathic |
| mesh[9].qualifier_ui | Q000150 |
| mesh[9].descriptor_ui | D016553 |
| mesh[9].is_major_topic | True |
| mesh[9].qualifier_name | complications |
| mesh[9].descriptor_name | Purpura, Thrombocytopenic, Idiopathic |
| mesh[10].qualifier_ui | |
| mesh[10].descriptor_ui | D011743 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | |
| mesh[10].descriptor_name | Pyrimidines |
| mesh[11].qualifier_ui | Q000009 |
| mesh[11].descriptor_ui | D011725 |
| mesh[11].is_major_topic | True |
| mesh[11].qualifier_name | adverse effects |
| mesh[11].descriptor_name | Pyridines |
| mesh[12].qualifier_ui | Q000627 |
| mesh[12].descriptor_ui | D011725 |
| mesh[12].is_major_topic | True |
| mesh[12].qualifier_name | therapeutic use |
| mesh[12].descriptor_name | Pyridines |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D000631 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Aminopyridines |
| mesh[14].qualifier_ui | |
| mesh[14].descriptor_ui | D009025 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | |
| mesh[14].descriptor_name | Morpholines |
| mesh[15].qualifier_ui | Q000009 |
| mesh[15].descriptor_ui | D047428 |
| mesh[15].is_major_topic | True |
| mesh[15].qualifier_name | adverse effects |
| mesh[15].descriptor_name | Protein Kinase Inhibitors |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D012307 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | Risk Factors |
| mesh[17].qualifier_ui | |
| mesh[17].descriptor_ui | D000208 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | |
| mesh[17].descriptor_name | Acute Disease |
| type | article |
| title | Fostamatinib and the risk of acute aortic dissection in immune thrombocytopenia |
| biblio.issue | 12 |
| biblio.volume | 91 |
| biblio.last_page | 3541 |
| biblio.first_page | 3537 |
| topics[0].id | https://openalex.org/T10746 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2720 |
| topics[0].subfield.display_name | Hematology |
| topics[0].display_name | Platelet Disorders and Treatments |
| topics[1].id | https://openalex.org/T11064 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9976999759674072 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2705 |
| topics[1].subfield.display_name | Cardiology and Cardiovascular Medicine |
| topics[1].display_name | Antiplatelet Therapy and Cardiovascular Diseases |
| topics[2].id | https://openalex.org/T11628 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.994700014591217 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2716 |
| topics[2].subfield.display_name | Genetics |
| topics[2].display_name | Myeloproliferative Neoplasms: Diagnosis and Treatment |
| is_xpac | False |
| apc_list.value | 4330 |
| apc_list.currency | USD |
| apc_list.value_usd | 4330 |
| apc_paid.value | 4330 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 4330 |
| language | en |
| locations[0].id | doi:10.1002/bcp.70289 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S13842274 |
| locations[0].source.issn | 0306-5251, 1365-2125 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0306-5251 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | British Journal of Clinical Pharmacology |
| locations[0].source.host_organization | https://openalex.org/P4310320595 |
| locations[0].source.host_organization_name | Wiley |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320595 |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bcp.70289 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | British Journal of Clinical Pharmacology |
| locations[0].landing_page_url | https://doi.org/10.1002/bcp.70289 |
| locations[1].id | pmid:40962713 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | British journal of clinical pharmacology |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/40962713 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5092602604 |
| authorships[0].author.orcid | https://orcid.org/0009-0001-7078-1880 |
| authorships[0].author.display_name | Paul Dalmas |
| authorships[0].countries | FR |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I21491767 |
| authorships[0].affiliations[0].raw_affiliation_string | Aix Marseille University, APHM, Internal Medicine Department, La Timone Hospital, Marseille, France |
| authorships[0].institutions[0].id | https://openalex.org/I21491767 |
| authorships[0].institutions[0].ror | https://ror.org/035xkbk20 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I21491767 |
| authorships[0].institutions[0].country_code | FR |
| authorships[0].institutions[0].display_name | Aix-Marseille Université |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Paul Dalmas |
| authorships[0].is_corresponding | True |
| authorships[0].raw_affiliation_strings | Aix Marseille University, APHM, Internal Medicine Department, La Timone Hospital, Marseille, France |
| authorships[1].author.id | https://openalex.org/A5077867556 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-9453-9039 |
| authorships[1].author.display_name | Alexis Théron |
| authorships[1].countries | FR |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I154526488, https://openalex.org/I21491767 |
| authorships[1].affiliations[0].raw_affiliation_string | Aix-Marseille University, INSERM, MMG U1251, Marseille, France |
| authorships[1].affiliations[1].institution_ids | https://openalex.org/I4210162909 |
| authorships[1].affiliations[1].raw_affiliation_string | Department of cardiac Surgery, La Timone Hospital, Marseille, France |
| authorships[1].institutions[0].id | https://openalex.org/I21491767 |
| authorships[1].institutions[0].ror | https://ror.org/035xkbk20 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I21491767 |
| authorships[1].institutions[0].country_code | FR |
| authorships[1].institutions[0].display_name | Aix-Marseille Université |
| authorships[1].institutions[1].id | https://openalex.org/I4210162909 |
| authorships[1].institutions[1].ror | https://ror.org/05jrr4320 |
| authorships[1].institutions[1].type | healthcare |
| authorships[1].institutions[1].lineage | https://openalex.org/I4210087487, https://openalex.org/I4210162909 |
| authorships[1].institutions[1].country_code | FR |
| authorships[1].institutions[1].display_name | Hôpital de la Timone |
| authorships[1].institutions[2].id | https://openalex.org/I154526488 |
| authorships[1].institutions[2].ror | https://ror.org/02vjkv261 |
| authorships[1].institutions[2].type | government |
| authorships[1].institutions[2].lineage | https://openalex.org/I154526488 |
| authorships[1].institutions[2].country_code | FR |
| authorships[1].institutions[2].display_name | Inserm |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Alexis Theron |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Aix-Marseille University, INSERM, MMG U1251, Marseille, France, Department of cardiac Surgery, La Timone Hospital, Marseille, France |
| authorships[2].author.id | https://openalex.org/A5013724472 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Rita Badaoui |
| authorships[2].countries | FR |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210162909 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of cardiac Surgery, La Timone Hospital, Marseille, France |
| authorships[2].institutions[0].id | https://openalex.org/I4210162909 |
| authorships[2].institutions[0].ror | https://ror.org/05jrr4320 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210087487, https://openalex.org/I4210162909 |
| authorships[2].institutions[0].country_code | FR |
| authorships[2].institutions[0].display_name | Hôpital de la Timone |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Rita Badaoui |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of cardiac Surgery, La Timone Hospital, Marseille, France |
| authorships[3].author.id | https://openalex.org/A5078680235 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-0811-418X |
| authorships[3].author.display_name | Stéphane Zaffran |
| authorships[3].countries | FR |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I154526488, https://openalex.org/I21491767 |
| authorships[3].affiliations[0].raw_affiliation_string | Aix-Marseille University, INSERM, MMG U1251, Marseille, France |
| authorships[3].institutions[0].id | https://openalex.org/I21491767 |
| authorships[3].institutions[0].ror | https://ror.org/035xkbk20 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I21491767 |
| authorships[3].institutions[0].country_code | FR |
| authorships[3].institutions[0].display_name | Aix-Marseille Université |
| authorships[3].institutions[1].id | https://openalex.org/I154526488 |
| authorships[3].institutions[1].ror | https://ror.org/02vjkv261 |
| authorships[3].institutions[1].type | government |
| authorships[3].institutions[1].lineage | https://openalex.org/I154526488 |
| authorships[3].institutions[1].country_code | FR |
| authorships[3].institutions[1].display_name | Inserm |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Stéphane Zaffran |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Aix-Marseille University, INSERM, MMG U1251, Marseille, France |
| authorships[4].author.id | https://openalex.org/A5119661690 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Rayid Mchinda |
| authorships[4].affiliations[0].raw_affiliation_string | Radiology Department La Timone Hospital, Assistance Publique Des Hôpitaux de Marseille Marseille 05 France |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Rayid Mchinda |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Radiology Department La Timone Hospital, Assistance Publique Des Hôpitaux de Marseille Marseille 05 France |
| authorships[5].author.id | https://openalex.org/A5016176687 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-7172-7835 |
| authorships[5].author.display_name | Joëlle Micallef |
| authorships[5].countries | FR |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I21491767, https://openalex.org/I4210134195 |
| authorships[5].affiliations[0].raw_affiliation_string | Aix Marseille University, APHM, Pharmacologie Clinique & Pharmacosurveillance Department Sainte Marguerite Hospital and Regional Pharmacovigilance Center Marseille France |
| authorships[5].institutions[0].id | https://openalex.org/I21491767 |
| authorships[5].institutions[0].ror | https://ror.org/035xkbk20 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I21491767 |
| authorships[5].institutions[0].country_code | FR |
| authorships[5].institutions[0].display_name | Aix-Marseille Université |
| authorships[5].institutions[1].id | https://openalex.org/I4210134195 |
| authorships[5].institutions[1].ror | https://ror.org/0338wkj94 |
| authorships[5].institutions[1].type | healthcare |
| authorships[5].institutions[1].lineage | https://openalex.org/I4210087487, https://openalex.org/I4210134195 |
| authorships[5].institutions[1].country_code | FR |
| authorships[5].institutions[1].display_name | Hôpital Sainte-Marguerite |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Joelle Micallef |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Aix Marseille University, APHM, Pharmacologie Clinique & Pharmacosurveillance Department Sainte Marguerite Hospital and Regional Pharmacovigilance Center Marseille France |
| authorships[6].author.id | https://openalex.org/A5036285321 |
| authorships[6].author.orcid | https://orcid.org/0000-0001-9449-3392 |
| authorships[6].author.display_name | N. Schleinitz |
| authorships[6].countries | FR |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I21491767 |
| authorships[6].affiliations[0].raw_affiliation_string | Aix Marseille University, APHM, Internal Medicine Department, La Timone Hospital, Marseille, France |
| authorships[6].institutions[0].id | https://openalex.org/I21491767 |
| authorships[6].institutions[0].ror | https://ror.org/035xkbk20 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I21491767 |
| authorships[6].institutions[0].country_code | FR |
| authorships[6].institutions[0].display_name | Aix-Marseille Université |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Nicolas Schleinitz |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Aix Marseille University, APHM, Internal Medicine Department, La Timone Hospital, Marseille, France |
| authorships[7].author.id | https://openalex.org/A5039260691 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-1179-8113 |
| authorships[7].author.display_name | Mikaël Ebbo |
| authorships[7].countries | FR |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I21491767 |
| authorships[7].affiliations[0].raw_affiliation_string | Aix Marseille University, APHM, Internal Medicine Department, La Timone Hospital, Marseille, France |
| authorships[7].institutions[0].id | https://openalex.org/I21491767 |
| authorships[7].institutions[0].ror | https://ror.org/035xkbk20 |
| authorships[7].institutions[0].type | education |
| authorships[7].institutions[0].lineage | https://openalex.org/I21491767 |
| authorships[7].institutions[0].country_code | FR |
| authorships[7].institutions[0].display_name | Aix-Marseille Université |
| authorships[7].author_position | last |
| authorships[7].raw_author_name | Mikael Ebbo |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Aix Marseille University, APHM, Internal Medicine Department, La Timone Hospital, Marseille, France |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bcp.70289 |
| open_access.oa_status | hybrid |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Fostamatinib and the risk of acute aortic dissection in immune thrombocytopenia |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-28T02:08:47.144824 |
| primary_topic.id | https://openalex.org/T10746 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2720 |
| primary_topic.subfield.display_name | Hematology |
| primary_topic.display_name | Platelet Disorders and Treatments |
| cited_by_count | 0 |
| locations_count | 2 |
| best_oa_location.id | doi:10.1002/bcp.70289 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S13842274 |
| best_oa_location.source.issn | 0306-5251, 1365-2125 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 0306-5251 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | British Journal of Clinical Pharmacology |
| best_oa_location.source.host_organization | https://openalex.org/P4310320595 |
| best_oa_location.source.host_organization_name | Wiley |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320595 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bcp.70289 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | British Journal of Clinical Pharmacology |
| best_oa_location.landing_page_url | https://doi.org/10.1002/bcp.70289 |
| primary_location.id | doi:10.1002/bcp.70289 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S13842274 |
| primary_location.source.issn | 0306-5251, 1365-2125 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0306-5251 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | British Journal of Clinical Pharmacology |
| primary_location.source.host_organization | https://openalex.org/P4310320595 |
| primary_location.source.host_organization_name | Wiley |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320595 |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bcp.70289 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | British Journal of Clinical Pharmacology |
| primary_location.landing_page_url | https://doi.org/10.1002/bcp.70289 |
| publication_date | 2025-09-17 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W2993666578, https://openalex.org/W2799711263, https://openalex.org/W4399394849, https://openalex.org/W4211116063, https://openalex.org/W4389133863, https://openalex.org/W3093206872, https://openalex.org/W4308197761, https://openalex.org/W2157883701, https://openalex.org/W3106880786, https://openalex.org/W4389957530, https://openalex.org/W2108314670, https://openalex.org/W3208102345, https://openalex.org/W4390025027, https://openalex.org/W4390030366, https://openalex.org/W4390032737, https://openalex.org/W4310119387, https://openalex.org/W1984073642 |
| referenced_works_count | 17 |
| abstract_inverted_index.( | 33 |
| abstract_inverted_index.) | 35 |
| abstract_inverted_index., | 27 |
| abstract_inverted_index.3 | 63 |
| abstract_inverted_index.A | 68, 102 |
| abstract_inverted_index.a | 4, 21, 38, 46, 56, 72, 87, 117, 126, 149, 182 |
| abstract_inverted_index.1) | 105 |
| abstract_inverted_index.We | 44 |
| abstract_inverted_index.an | 28, 49 |
| abstract_inverted_index.be | 199, 204 |
| abstract_inverted_index.by | 9, 191 |
| abstract_inverted_index.in | 41, 55, 120, 131, 210, 230 |
| abstract_inverted_index.is | 3, 24, 37 |
| abstract_inverted_index.of | 48, 75, 112, 138, 169, 228 |
| abstract_inverted_index.on | 171 |
| abstract_inverted_index.or | 18 |
| abstract_inverted_index.to | 16, 78, 125, 147, 222 |
| abstract_inverted_index.us | 146 |
| abstract_inverted_index.25% | 118 |
| abstract_inverted_index.AAD | 106 |
| abstract_inverted_index.ITP | 231 |
| abstract_inverted_index.SYK | 34, 122, 160, 192 |
| abstract_inverted_index.She | 91 |
| abstract_inverted_index.The | 136 |
| abstract_inverted_index.and | 85, 97, 154, 166, 187, 193, 232 |
| abstract_inverted_index.are | 220 |
| abstract_inverted_index.for | 216 |
| abstract_inverted_index.her | 113 |
| abstract_inverted_index.led | 145 |
| abstract_inverted_index.may | 174 |
| abstract_inverted_index.the | 224 |
| abstract_inverted_index.was | 81, 98 |
| abstract_inverted_index.AAD, | 188 |
| abstract_inverted_index.AAD. | 155, 217 |
| abstract_inverted_index.ITP, | 76 |
| abstract_inverted_index.This | 179 |
| abstract_inverted_index.VEGF | 172 |
| abstract_inverted_index.case | 47, 180 |
| abstract_inverted_index.cell | 134 |
| abstract_inverted_index.data | 157 |
| abstract_inverted_index.even | 209 |
| abstract_inverted_index.link | 151 |
| abstract_inverted_index.most | 13 |
| abstract_inverted_index.oral | 29 |
| abstract_inverted_index.pain | 96 |
| abstract_inverted_index.rare | 5 |
| abstract_inverted_index.risk | 61, 214 |
| abstract_inverted_index.that | 159 |
| abstract_inverted_index.type | 104 |
| abstract_inverted_index.wall | 164 |
| abstract_inverted_index.when | 206 |
| abstract_inverted_index.with | 71, 83, 93, 100 |
| abstract_inverted_index.(AAD) | 53 |
| abstract_inverted_index.(ITP) | 2 |
| abstract_inverted_index.VEGFR | 194 |
| abstract_inverted_index.While | 12, 196 |
| abstract_inverted_index.acute | 50 |
| abstract_inverted_index.after | 65 |
| abstract_inverted_index.chest | 95 |
| abstract_inverted_index.known | 213 |
| abstract_inverted_index.other | 233 |
| abstract_inverted_index.small | 22 |
| abstract_inverted_index.these | 42 |
| abstract_inverted_index.woman | 70 |
| abstract_inverted_index.Immune | 0 |
| abstract_inverted_index.aortic | 51, 114, 163 |
| abstract_inverted_index.cannot | 198 |
| abstract_inverted_index.cases. | 43 |
| abstract_inverted_index.kinase | 32 |
| abstract_inverted_index.months | 64 |
| abstract_inverted_index.muscle | 133 |
| abstract_inverted_index.needed | 221 |
| abstract_inverted_index.option | 40 |
| abstract_inverted_index.report | 45 |
| abstract_inverted_index.safety | 226 |
| abstract_inverted_index.should | 203 |
| abstract_inverted_index.showed | 116 |
| abstract_inverted_index.smooth | 132 |
| abstract_inverted_index.spleen | 30 |
| abstract_inverted_index.subset | 23 |
| abstract_inverted_index.sudden | 94 |
| abstract_inverted_index.tissue | 115 |
| abstract_inverted_index.weaken | 176 |
| abstract_inverted_index.Further | 218 |
| abstract_inverted_index.absence | 137 |
| abstract_inverted_index.between | 152, 185 |
| abstract_inverted_index.clarify | 223 |
| abstract_inverted_index.control | 127 |
| abstract_inverted_index.effects | 168 |
| abstract_inverted_index.explore | 148 |
| abstract_inverted_index.factors | 215 |
| abstract_inverted_index.further | 175 |
| abstract_inverted_index.genetic | 143 |
| abstract_inverted_index.history | 74 |
| abstract_inverted_index.patient | 57 |
| abstract_inverted_index.profile | 227 |
| abstract_inverted_index.respond | 15 |
| abstract_inverted_index.sample, | 128 |
| abstract_inverted_index.studies | 219 |
| abstract_inverted_index.suggest | 158 |
| abstract_inverted_index.treated | 82 |
| abstract_inverted_index.without | 58, 129, 212 |
| abstract_inverted_index.(DeBakey | 103 |
| abstract_inverted_index.Stanford | 101 |
| abstract_inverted_index.achieved | 86 |
| abstract_inverted_index.analysis | 111 |
| abstract_inverted_index.compared | 124 |
| abstract_inverted_index.complete | 88 |
| abstract_inverted_index.disorder | 7 |
| abstract_inverted_index.factors, | 62 |
| abstract_inverted_index.first‐ | 17 |
| abstract_inverted_index.markers. | 135 |
| abstract_inverted_index.mediated | 190 |
| abstract_inverted_index.multiple | 79 |
| abstract_inverted_index.patients | 14, 211 |
| abstract_inverted_index.platelet | 10 |
| abstract_inverted_index.possible | 183 |
| abstract_inverted_index.smoking, | 142 |
| abstract_inverted_index.surgery. | 109 |
| abstract_inverted_index.tyrosine | 31 |
| abstract_inverted_index.vascular | 177, 225 |
| abstract_inverted_index.vigilant | 205 |
| abstract_inverted_index.30‐year | 73 |
| abstract_inverted_index.causality | 197 |
| abstract_inverted_index.diagnosed | 99 |
| abstract_inverted_index.emergency | 108 |
| abstract_inverted_index.occurring | 54 |
| abstract_inverted_index.potential | 150 |
| abstract_inverted_index.presented | 92 |
| abstract_inverted_index.receptors | 173 |
| abstract_inverted_index.reduction | 119 |
| abstract_inverted_index.requiring | 107 |
| abstract_inverted_index.response. | 90 |
| abstract_inverted_index.settings. | 234 |
| abstract_inverted_index.alteration | 130 |
| abstract_inverted_index.autoimmune | 6 |
| abstract_inverted_index.clinicians | 202 |
| abstract_inverted_index.conditions | 140 |
| abstract_inverted_index.disorders) | 144 |
| abstract_inverted_index.dissection | 52 |
| abstract_inverted_index.expression | 123 |
| abstract_inverted_index.highlights | 181 |
| abstract_inverted_index.inhibition | 161 |
| abstract_inverted_index.inhibitor, | 36 |
| abstract_inverted_index.integrity. | 178 |
| abstract_inverted_index.therapies, | 20, 80 |
| abstract_inverted_index.association | 184 |
| abstract_inverted_index.exacerbates | 162 |
| abstract_inverted_index.inhibition. | 195 |
| abstract_inverted_index.initiation. | 67 |
| abstract_inverted_index.potentially | 189 |
| abstract_inverted_index.prescribing | 207 |
| abstract_inverted_index.therapeutic | 39 |
| abstract_inverted_index.traditional | 59 |
| abstract_inverted_index.Experimental | 156 |
| abstract_inverted_index.Fostamatinib | 26 |
| abstract_inverted_index.Histological | 110 |
| abstract_inverted_index.definitively | 200 |
| abstract_inverted_index.destruction. | 11 |
| abstract_inverted_index.established, | 201 |
| abstract_inverted_index.fostamatinib | 66, 84, 153, 170, 186, 229 |
| abstract_inverted_index.haematologic | 89 |
| abstract_inverted_index.off‐target | 167 |
| abstract_inverted_index.predisposing | 139 |
| abstract_inverted_index.unresponsive | 77 |
| abstract_inverted_index.characterized | 8 |
| abstract_inverted_index.fostamatinib, | 208 |
| abstract_inverted_index.second‐line | 19 |
| abstract_inverted_index.(hypertension, | 141 |
| abstract_inverted_index.cardiovascular | 60 |
| abstract_inverted_index.phosphorylated | 121 |
| abstract_inverted_index.vulnerability, | 165 |
| abstract_inverted_index.70‐year‐old | 69 |
| abstract_inverted_index.multirefractory. | 25 |
| abstract_inverted_index.thrombocytopenia | 1 |
| cited_by_percentile_year | |
| corresponding_author_ids | https://openalex.org/A5092602604 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 8 |
| corresponding_institution_ids | https://openalex.org/I21491767 |
| citation_normalized_percentile.value | 0.59729298 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |